Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Global Pharma Market Grows to US$1.18 Trillion in 2020, with Humira Maintaining No. 1 Title: IQVIA
June 11, 2021
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Takeda Boasts 10-Plus Immune-Harnessing Compounds in Early Pipeline: Oncology Update
June 10, 2021
- Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
- Kitasato Institute, Meiji Kick Off R&D of Ivermectin Derivatives-Based COVID-19 Meds
June 10, 2021
- Nippon Chemiphar, Sumitomo Dainippon Team Up on Antidepressant R&D
June 10, 2021
- Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
- Novo, Chiba University, Asahi City Join Hands to Combat Diabetes
June 9, 2021
- Takeda Chips in for Govt’s Workplace COVID-19 Immunization Drive
June 9, 2021
- Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
- FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
- Japan Ethical Drug Sales Down 2.4% in April: Crecon
June 8, 2021
- Keytruda Retrieves Top-Selling Crown in Japan in May: Encise
June 8, 2021
- Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
June 8, 2021
- Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
- Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
- Reps’ Face-to-Face Meetings Up 60% YOY in April, but Fall Shy of Prepandemic Level: Intage
June 7, 2021
- AstraZeneca Launches Exploratory Study to Predict Onset of ILD in NSCLC Patients on Imfinzi
June 7, 2021
- MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
- Aspen Japan to Be Renamed Sandoz Pharma in September
June 4, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…